CGNSF (Cognetivity Neurosciences) Research & Development: $0.00 Mil (TTM As of Oct. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cognetivity Neurosciences Research & Development?

Cognetivity Neurosciences CGNSF -99.00% Research & Development is $0.00 Mil as of Oct. 2023.

Research & Development is the aggregate amount of research and development expenses during the year. Cognetivity Neurosciences's Research & Development for the three months ended in Oct. 2023 was $0.03 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Oct. 2023 was $0.00 Mil.

Cognetivity Neurosciences  (OTCPK:CGNSF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cognetivity Neurosciences Research & Development Related Terms

Cognetivity Neurosciences Research & Development Historical Data

* Premium members only.

The historical data trend for Cognetivity Neurosciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cognetivity Neurosciences Research & Development Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Research & Development
Get a 7-Day Free Trial 0.55 0.38 0.06 0.39 0.45

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 -0.21 0.12 0.06 0.03

Cognetivity Neurosciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Cognetivity Neurosciences (CGNSF) has a Research & Development of $0.00 Mil as of Oct. 2023. Research and development expense is the total cost for research and development activities. View historical data on Cognetivity Neurosciences and its competitors.
Is Cognetivity Neurosciences' Research & Development too high?
Cognetivity Neurosciences' current Research & Development is $0.00 Mil.
How does Cognetivity Neurosciences' Research & Development compare to VEEV and GEHC?
Cognetivity Neurosciences' Research & Development of $0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cognetivity Neurosciences and its competitors. Cognetivity Neurosciences's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cognetivity Neurosciences stock overvalued right now?
Cognetivity Neurosciences (CGNSF) has a current Research & Development of $0.00 Mil. The current Research & Development is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cognetivity Neurosciences (CGNSF), the current Research & Development is $0.00 Mil as of Oct. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cognetivity Neurosciences Business Description

Address 800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.